You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Humalog® U-100 (insulin lispro injection)
100 units/mLHumalog® U-200 (insulin lispro injection)
200 units/mLHumalog® MIX50/50™ (50% insulin lispro protamine suspension 50% insulin lispro injection [rDNA origin])
100 units/mLHumalog® MIX75/25™ (75% insulin lispro protamine suspension 25% insulin lispro injection [rDNA origin])
100 units/mLThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is the Tempo™ Personalized Diabetes Management Platform approved to be used in pediatric population?
Tempo Personalized Diabetes Management Platform is not approved to be used in pediatric population.
Use in Pediatric Population
Tempo Personalized Diabetes Management Platform has not been investigated in pediatric population.1
Tempo Personalized Diabetes Management Platform is indicated for use in patients 18 years or older who have been diagnosed with type 1 or type 2 diabetes mellitus.1
Enclosed Prescribing Information
Reference
1TempoSmart App: United States [User Guide]. Indianapolis, IN: Eli Lilly and Company; 2024.
Date of Last Review: June 23, 2025